The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the pharmacokinetics (PK) and cardiac properties
of elacytarabine in patients with relapsed or refractory Acute Myeloid Leukaemia (AML). The
efficacy and tolerability of elacytarabine will also be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Clavis Pharma
Collaborators:
CardiaBase INC Research Learn & Confirm Syneos Health Theradex